GlassScriptPhysician profile
David Arthur Vaughn
NPI 1639339542
$6,820.56
in general payments reported to CMS, 2019-2025
28 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,540 · 2020: $180 · 2021: $152 · 2022: $483 · 2023: $89.94 · 2024: $135 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,412.93 | 2019-2025 | |
| Davol INC. | $211.42 | 2019-2023 | Bard 3dmax Mesh |
| Inari Medical, INC. | $208.82 | 2022 | |
| Medtronic, INC. | $159.10 | 2022 | |
| Smith+Nephew, INC. | $154.16 | 2021-2025 | Collagenase Santyl, Pico 7, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Kerecis Limited | $73.51 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ethicon US, LLC | $72.70 | 2020-2025 | Surgicel Nu-Knit, Echelon; Endopath |
| Takeda Pharmaceuticals U.S.A., INC. | $56.86 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $55.11 | 2025 | |
| Integra Lifesciences Corporation | $46.95 | 2022-2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Tela Bio, INC. | $39.83 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Covidien LP | $36.02 | 2019 | |
| Kci USA, INC. | $30.16 | 2022-2023 | Activ.A.C., Kerramax Care |
| Convatec INC. | $24.07 | 2024 | |
| Baxter Healthcare | $21.99 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.74 | 2019 | |
| Abbott Laboratories | $20.63 | 2021 | |
| Mozarc Medical US LLC | $19.94 | 2024 | Argyle |
| Teleflex LLC | $19.18 | 2021 | |
| Innocoll Pharmaceuticals Limited | $18.82 | 2021 | |
| Heron Therapeutics, INC. | $18.73 | 2025 | Zynrelef |
| Avanos Medical | $14.84 | 2019 | |
| Avita Medical Americas, LLC | $14.74 | 2025 | Cohealyx, Recell, Permeaderm |
| Solventum Corporation | $14.00 | 2025 | Activ.A.C. |
| Organogenesis INC. | $13.77 | 2024 | |
| Acell, INC. | $13.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2022 | |
| Portola Pharmaceuticals, LLC | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.